Results 161 to 170 of about 14,513 (189)
Some of the next articles are maybe not open access.
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1996
A comprehensive search of the published literature was undertaken to identify reports providing patient‐specific data relating to adverse neurologic events with cyclosporine. References cited in the articles identified by the search were manually reviewed to ensure that articles were pertinent.
openaire +2 more sources
A comprehensive search of the published literature was undertaken to identify reports providing patient‐specific data relating to adverse neurologic events with cyclosporine. References cited in the articles identified by the search were manually reviewed to ensure that articles were pertinent.
openaire +2 more sources
Clinical Biochemistry, 1991
Numerous analogues of cyclosporine A (CsA) have been produced and studied. Although these analogues have given considerable insight into structure-activity relationships, none have been shown to have the safety and efficacy of CsA. The most promising of these analogues is cyclosporine G (CsG) in which norvaline is substituted for alpha-aminobutyric ...
openaire +2 more sources
Numerous analogues of cyclosporine A (CsA) have been produced and studied. Although these analogues have given considerable insight into structure-activity relationships, none have been shown to have the safety and efficacy of CsA. The most promising of these analogues is cyclosporine G (CsG) in which norvaline is substituted for alpha-aminobutyric ...
openaire +2 more sources
Nephrologie, 1987
The author presents a summarized review concerning the use of cyclosporine in the control of graft rejection. He insists on the need to reduce as far as possible the cyclosporine dosage applied. This can be achieved in association with other drugs, such as azathioprine and/or steroids. The mechanism of action due to cyclosporine seems to be linked both
openaire +2 more sources
The author presents a summarized review concerning the use of cyclosporine in the control of graft rejection. He insists on the need to reduce as far as possible the cyclosporine dosage applied. This can be achieved in association with other drugs, such as azathioprine and/or steroids. The mechanism of action due to cyclosporine seems to be linked both
openaire +2 more sources